Rx Outsourcing Has Limits, Novartis' Vasella Says: R&D Supports Licensing
Executive Summary
A pharmaceutical company model based on in-licensing and marketing is not sustainable in the long run, Novartis CEO Daniel Vasella told the New York Society of Securities Analysts June 5.
You may also be interested in...
Bristol/DuPont Is Timely Deal: Will Disrupt Difficult 2002, Add To 2003
The Bristol/DuPont deal may offer Bristol-Myers Squibb a healthy dose of distraction heading through a difficult period of patent expirations.
Novartis Merger Stance: Firm "Prefers" No Deal For At Least Two Years
Novartis would "prefer" to wait two or three years before its next large transaction so it can focus on upcoming product launches, CFO Raymund Breu told the J.P. Morgan CEO conference on building shareholder value April 26.
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011